Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

China to Announce New National Drug Reimbursement List

publication date: Feb 1, 2017
According to sources, China is getting close to announcing a revised National Reimbursement Drug List (NRDL), the group of drugs covered by China's national insurance plan. There will be 300 additions, 130 of which will be chemical drugs. The rest will be traditional Chinese medicines. This is the first update of the NRDL since 2009. Last May, China negotiated steep price cuts on several breakthrough drugs, and these still-expensive treatments are expected to become part of the new list. These include Viread from GlaxoSmithKline; Iressa from AstraZeneca; and Icotinib from Zhejiang Beta Pharma. More details....

Stock Symbols: (NYSE: GSK) (NYSE: AZN )

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital